Johnson & Johnson's consumer division knows that much of its target audience consists of millennials, Hispanics and moms--and that those three groups have something else in common, too: soccer.
GlaxoSmithKline and Johnson & Johnson have settled a short-lived legal spat over GSK's allergy drug marketing claims--meaning that now, the only battle left will be the one for market share.
Johnson & Johnson and Google have partnered to create new robotic-assisted surgical platforms. The deal is the latest example of Google working with a major life sciences company to make a significant technological advance.
Johnson & Johnson has a Chinese strategy: long-term thinking. Despite an economic slowdown and regulatory crackdowns--and the example of other multinationals that have scaled back there--CEO Alex Gorsky figures it's worth it to ride out the storm.
Royal Philips and Janssen Pharmaceutical have partnered in a multiyear deal to create a hand-held, blood-based diagnostic for brain disorders. The test will be based on a product that Philips is already developing, the Minicare system. The financial details of the partnership were undisclosed.
Newcomers showed off at this year's American Academy of Dermatology meeting, with more than one touting Stelara-beating data--and prepping the market for an all-out psoriasis war.
Johnson & Johnson won a split decision in Philadelphia court Friday, in the latest Risperdal lawsuit to go to trial. A jury decided that J&J did fail to warn doctors that the antipsychotic drug could cause breast development in boys, Reuters reports.
Seventure Partners has added €25 million ($27 million) to its microbiome investment fund, bringing the total under management to €100 million. The move ups the financial firepower of the fund--which has invested in 5 companies since it started late in 2013--at a time when microbiome R&D is starting to take off.
J&J has snapped up XO1 for an undisclosed sum. It's a single-asset biotech offering a second-generation antithrombin to J&J's Xarelto. And it's the first to be sold off from a portfolio of 16 molecules that Index Ventures put together after assembling one of the original "asset-centric" funds.
When hepatitis C drugmakers started wooing payers with discounts, the cost cuts made the difference between an overwhelming burden and cost-effective spending. So say two new studies looking at the cost of treating the disease with a new generation of quite effective--but very expensive--treatments.